Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Study ID
- NCT00066391
- Phase
- PHASE2
- Status
- Completed
Conditions
- Penile Cancer
Eligibility Criteria
- Sex
- MALE
- Age
- N/A - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- cisplatin — DRUG
- irinotecan hydrochloride — DRUG
- neoadjuvant therapy — PROCEDURE
Study Details
RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Combining irinotecan with cisplatin may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining irinotecan with cisplatin in treating patients who have locally advanced or metastatic penile cancer.
Key Dates
- Start date
- Jun 30, 2003
- Status verified
- Sep 2012
- Primary completion
- Jan 31, 2006
Study Design
- Primary purpose
- TREATMENT
Primary Outcome Measure
Objective response rate measured by RECIST at 8 weeks after completion of study treatment
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersPHASE1/PHASE2 · Recruiting · Christian Hinrichs · New Brunswick, New Jersey
- E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersPHASE2 · Recruiting · Christian Hinrichs · Bethesda, Maryland
- A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of InterestRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts